Organic Active Ingredients TRIZ Cases

Topical KX-01 dosing treats and helps prevent actinic keratosis while reducing local skin reactions and adverse side effects.

A coated core-particle composition turns self-emulsifying liquids into tablet-ready granules while preserving solubility and absorption stability.

Controlled warm milling and stabilizers keep tegavivint particles below 0.2 microns for stable bioavailable inhalation and parenteral use.

Substituted benzimidazoles inhibit TLR9 while improving selectivity over TLR7/8, stability, and bioavailability for fibrotic disease treatment.

A buffered isotonic furosemide liquid balances pH and concentration to enable stable, less painful subcutaneous self-administration.

A dual preservative and suspending system keeps atomoxetine oral suspension stable, redispersible, palatable, and microbially protected.

Personalized bucindolol dosing by ADRB1 genotype and CYP2D6 status helps reduce atrial fibrillation in heart failure with fewer side effects.

Pressurized heterogeneous aerosolization improves olfactory-region dosing while limiting dripping, swallowing, and systemic side effects.

Low-permeability EP4 agonists concentrate in gastrointestinal and pulmonary tissues to treat disease while limiting cardiovascular side effects.

A glycosylated oleanolic acid compound lowers inflammatory markers and intestinal permeability in ulcerative colitis with Mesalazine-like efficacy.

A buffered high-concentration furosemide liquid balances stability, low injection pain, and self-administered subcutaneous delivery.

Blocking EGFR signaling in TRPV3-linked keratoderma can clear hyperkeratosis, relieve pain, and support sustained remission.

Modified bile acid derivatives resist intestinal BSH and 7α-dehydroxylase, prolong gut activity, and improve fatty liver and glucose metabolism.

A buffered furosemide liquid at pH 6.5-8.5 improves solution stability and enables less painful subcutaneous dosing outside IV settings.

A thickened otic carrier keeps antibacterial, antifungal, and anti-inflammatory agents in the ear canal for days after one application.

Co-administered vector vaccines, cytokines, and checkpoint inhibitors boost memory T-cell formation and sustain anti-cancer immune response.

A flowable chitosan gel reaches hidden jaw hemangioma hemorrhage points, forms local pressure for rapid hemostasis, and helps inhibit bacteria.

Targeted anti-HER2 immunoconjugates combine specific HER2 binding with cytotoxic payloads to inhibit tumor cell proliferation and improve response.

A buffered high-concentration furosemide liquid enables self-administered subcutaneous dosing while balancing stability, efficacy, and injection comfort.

Fluorine-substituted cyclohexene GABA analogues selectively inhibit OAT to curb cancer cell proliferation and tumor growth.

A colored alginate and cross-linker pair makes cartilage application and gel coat formation visible, improving fixation and limiting spread.

Defined free-form and fumaric acid crystal forms improve stability, oral absorbability, and brain penetration for HER2 tumor treatment.

A controlled oral minoxidil formulation extends serum exposure and duration of action for hair loss treatment while reducing rapid-absorption side effects.

Novel pyrazole derivatives act as CFTR correctors and potentiators to address mutation-specific trafficking and gating defects in cystic fibrosis.

Zinc-treated bamboo leaves and nano-impact grinding preserve emerald color, ultrafine particle size, and nutrient stability for food use.

DNA-encoded anti-PcrV and anti-Psl antibodies enable sustained in vivo protection against Pseudomonas infection and biofilm formation.

Selective heterocyclic MCT4 inhibitors reduce cancer cell lactate export while avoiding MCT1 off-target inhibition and improving potency.

Selective side-product formation plus distillation and extraction enables high-purity cannabigerol production without costly chromatography.

By combining a KRAS G12D inhibitor with a dual RAF/MEK inhibitor, this case shows synergistic suppression of tumor cell proliferation and survival.

Benzothiazones are tuned to selectively block Tau-SH3 interactions, helping reduce Aβ-induced neuronal dysfunction and cognitive deficits.

Tailored amino acid formulations exclude serine and glycine to starve tumors while improving efficacy for patient-specific cancer treatment.

pH-responsive ionizable lipids protect nucleic acids yet enable endosomal release, boosting mRNA expression at lower doses with fewer adverse reactions.

Dual IRAK and FLT3 inhibition targets adaptive resistance in AML and MDS while supporting longer response and improved survival.

Formula I compounds broaden KRAS inhibition across wild type and multiple mutations, including resistant cancers beyond G12C-focused drugs.

AR gene testing identifies prostate cancer patients more likely to respond to CYP11A1 inhibitors by blocking upstream steroid biosynthesis.

Heteroaryl derivatives target EGFR and HER2, including C797S-resistant mutants, to suppress kinase activity and cancer cell proliferation.

A pyranochromene eye composition treats degenerative eye disease by protecting mitochondria and reducing injection burden and VEGF-related side effects.

Novel YAP/TEAD modulators constrain Hippo pathway signaling, reduce target gene expression, and offer a route to control tumor growth.

Combining NAD precursors, boosters, and CD38 inhibitors raises NAD+ more effectively by overcoming rate limits and enzymatic degradation.

Bicyclic cGP analogs restore IGF-1 bioavailability and rescue dendritic defects linked to Pitt Hopkins Syndrome symptoms.

Targeting SHP2 offers a monotherapy option for resistant solid tumors, reducing tumor burden and extending progression-free survival.

Azepine-fused compounds target RIPK1 kinase with high selectivity to block pro-inflammatory signaling while limiting off-target kinase effects.

A cyclic amine derivative protects neurons and accelerates myelination to treat diverse peripheral neuropathies with fewer limits than current drugs.

Nitro-functionalized dopamine sutured into gelatin hydrogels improves wet adhesion, conductivity, and cytocompatibility for tissue repair.

Targeting ARNT degradation helps disrupt hypoxic signaling in VHL-mutant cancers, addressing progression and resistance to chemotherapy and radiation.

A ferric meglumine composition removes carbohydrate-related allergy and sugar burdens while enabling parenteral and oral iron use.

Controlled oral minoxidil release maintains therapeutic levels longer while lowering peak serum exposure and adverse effects in hair loss treatment.

Covalent drug-oligonucleotide conjugation improves solubility, cellular uptake, and multi-pathway inflammation regulation without extra carriers.

Specific excipients and particle-size control improve pemafibrate homogeneity and content uniformity, reducing batch-to-batch variation.

Targeted RBM39 degradation with pyrazole-4-sulfonamides modulates splicing and drives selective cancer cell death.

Oxidative stress and elastin fiber breaks weaken the aorta; cobinamide helps preserve integrity and limit aortic dilation.

Targeted cationic charges help porphyrin photosensitizers penetrate biofilms, generate ROS, and achieve up to 4–6 log-unit bacterial reduction.

PLGA nanoparticles and a thermoreversible nanogel sustain local sunitinib release for AMD, reducing dosing frequency and adverse effects.

Selective D2, D3, and 5-HT2A antagonism targets cognitive gaps while reduced H1 affinity helps limit sedation and obesity.

Crystalline forms of a menin inhibitor target the menin-MLL interaction to disrupt oncogenic signaling in AML and ALL.

CLIP-based 3D printing preserves drug stability while tuning intravaginal ring geometry, loading capacity, and release rates.

Combining a KRASG12C inhibitor with bevacizumab targets tumor proliferation and angiogenesis to improve treatment of solid tumors.

A controlled-release skin delivery system maintains dronabinol plasma concentrations while reducing dosing frequency and avoiding hepatic first-pass metabolism.

Compound 1 targets 5-HT, SERT, D2, sodium channels, and norepinephrine transporters to support CNS treatment with fewer side effects.

Titrated intravenous iloprost uses vasodilation and anti-platelet activity to reduce digit amputation risk in severe frostbite.

Novel oxindole compounds inhibit DGAT2 to modulate lipid metabolism in hepatic steatosis, NASH, diabetes, and obesity.

Stoichiometric tosylate formation and solvent evaporation improve low-pH solubility and long-term storage stability for an anti-tubercular carboxamide.

An indole-linked pyrazolopyridine compound addresses GLP-1 agonist limits in oral bioavailability and metabolic stability.

Carbazole derivatives sensitize LKB1-deficient cancer cells to paclitaxel, supporting lower doses and reduced resistance and toxicity.

Short IGFBP-derived immodulin peptides drive IGF-independent monocyte differentiation while extensions improve peptide stability and potency.

Acetaminophen and ibuprofen prodrugs in an adhesive matrix support stable skin permeation and enzymatic conversion while avoiding oral GI exposure.

Acidic pH and a solvent system stabilize oral pilocarpine for room-temperature storage without boric acid or benzalkonium chloride.

Selective degradation of mutant polyQ proteins uses a substituted bicyclic compound to enhance autophagy while sparing wild-type proteins.

Conventional treatments may not effectively remove dysregulated BCL6; this approach recruits CRBN to drive ubiquitination and proteasomal degradation.

Modified R1–R6 groups and heterocyclic systems tune KRAS G12D inhibitor potency while supporting selective activity against cancer cells.

Reducing oxidative damage with TUDCA and PBA helps protect neural cells, regulate redox balance, and improve viability.

Combining olutasidenib with temozolomide as maintenance therapy targets IDH1-mutant CNS tumors and may reduce tumor size or support remission.

Compounds that covalently bind tau at Cys291 and Cys322 inhibit aggregation in vitro and reduce tau-induced pathology in vivo.

FLT3-mutated AML can leave bone marrow blasts after treatment; crenolanib reduces blasts in blood and marrow to support survival.

Intravitreal trehalose stabilizes lens proteins and neutralizes reactive oxygen species for longer protection after vitrectomy.

Modified paracetamol compounds aim to preserve analgesic and antipyretic effects while reducing hepatotoxicity and overdose risk.

An ALS regimen combining quercetin, vitamins B3 and C, and zafirlukast targets neuroinflammation and preserves mitochondrial function.

Muco-adhesive and enteric-coated components combine immediate and controlled release to limit levodopa fluctuations and extend therapeutic action.

CPT-2008 modulates mitochondrial ROS and electron transport to address dysfunction linked to cancer and neurodegenerative disease.

Antioxidant additives protect post-surgical corticosteroid eye drops from oxidation, acidic degradation, and pH drift during storage.

Targeting autoreactive tissue-resident memory T cells with IL-15 or receptor inhibitors aims to prevent relapse and maintain repigmentation in vitiligo.

RNA-targeted compounds regulate c-MYC mRNA translation and transcription, bypassing hard-to-drug MYC protein regions to limit tumor growth.

Replacing unsuitable ingredients with N-acetylated oligosaccharides supports intestinal muscle thickness, motility, feeding tolerance, and SIBO prevention in young children.

Non-covalent KRAS G12D binding enables PROTAC-driven degradation while avoiding the catalytic-cycle limits of covalent inhibition.

A deep-learning model selects optimal cut sites to make template-free genome-editing repair outcomes more predictable.

Combining at least 70% abiraterone acetate with selected excipients enables one-tablet dosing, fast water disintegration, and stable storage.

Slow ramp-up and patient non-response limit current treatments; enriched benzofuran enantiomers selectively bind CNS receptors for faster effects.

Selective alpha-7 nAChR agonists target cognitive impairment while limiting the side effects linked to non-selective receptor activation.

Existing PPIs and P-CABs offer acid inhibition but limited structural diversity; this case uses pyrrolopyrazole derivatives to target H+/K+-ATPase.

Existing surgical barriers can fail in blood; hydrophobic chitosan maintains a cohesive tissue barrier while reducing post-surgical adhesion.

Electrophilic compounds covalently bind cysteine 12 to inhibit both GTP- and GDP-bound KRAS G12C, addressing colorectal cancer pathway rebound.

Ionizable amino lipids help overcome low cell permeability and nucleic acid instability while supporting targeted therapeutic delivery.

Heat shock response treatment for spinal muscular atrophy addresses exon 7 mis-splicing to raise full-length SMN2 mRNA and protein.

Novel macrocycle compounds target KRAS G12C, G12D, and G12V while addressing acquired resistance and pharmacokinetic limits.

Modified dsRNA agents silence KHK mRNA to reduce fructose metabolism linked to fatty liver and dyslipidemia.

Controlled solvent, temperature, and pH conditions convert unstable Form A into Form HB, supporting stable large-scale drug manufacturing.

Quinolone degraders recruit CRBN to form ternary complexes with BCL6, enabling ubiquitination and proteasomal removal where direct inhibition is limited.

Inhaled imidazole derivatives inhibit ALK5 in lung compartments while limiting systemic exposure for improved safety and tolerability.

Real-time reliability checks on pressure, timing, and morphology support closed-loop infusion changes when blood pressure leaves its target range.

Addressing inefficient CNS delivery and multi-target silencing, this case links dsRNAs with lipophilic groups in modified RNA structures.

A collagen-based biocomposite matrix entraps probiotics to enhance stability and adhesion within the vaginal environment.

Formula I compounds inhibit cathepsin L and B, resolving the lack of effective inhibitors for managing SARS-CoV-2 infections.

Tetracyclic compounds act as potent dopamine ligands with preferential affinity for D3 receptors.

Inhibiting Hom-1 expression with nucleic acid molecules abates tissue inflammation and protects mucosal epithelial cell viability.

Chromatographic analysis detects 2-hydroxyglutarate levels to identify IDH1 and IDH2 mutations, enabling targeted therapy selection.

Water-soluble film formers in the coating matrix mediate dissolution, resolving low solubility constraints to improve bioavailability.

Replacing EDC-HCl with thionyl chloride produces thermodynamically stable Form C, resolving instability issues in solid dosage formulations.

Pentameric type A procyanidin composition manages broncho-constrictive conditions without adverse cardiovascular side effects.

A benzisoquinoline diketone compound targets tumors with low NNMT gene expression and high DNA methylation levels.

Disposable irrigation devices deliver composite antimicrobial solutions to reduce amputation risks and infection rates in diabetic foot ulcers.

Dicarboxylic acid esters suppress stickiness in high-concentration anticholinergic formulations, maintaining therapeutic effectiveness while improving comfort.

Dual-promoter nucleic acid constructs exploit hyperactive RAS pathways to drive toxin expression in cancer cells while sparing normal tissues.

Formula I compounds activate AT2 receptors while minimizing cytochrome P450 inhibition to reduce drug interactions.

A novel cationic lipid formulation forms stable particles with nucleic acids.

Beta-hydroxy-beta-methylbutyrate modulates autophagy to resolve the trade-off between improving fat metabolism and preserving muscle strength.

A multipart fluid system manages anticoagulation and calcium levels in extracorporeal blood circuits.

Segmenting adult tablets into precise oral films eliminates dosing inaccuracies and choking risks for children.

Sodium salt of 3-pentylphenylacetic acid treats blood and renal disorders by reducing toxicity while maintaining therapeutic efficacy.

A seven-membered ring compound inhibits chymase activity while maintaining structural integrity in biological fluids.

Timed testosterone and 5-HT1A agonist dosing overcomes delayed onset by aligning peak plasma levels with neural disinhibition.

Segmenting the fluid into acidic and alkaline components prevents icodextrin decomposition and coloring while restoring physiological pH compatibility.

dsRNA agents degrade TMPRSS6 transcripts to increase hepcidin levels, resolving ineffective iron overload management in thalassemia.

A composite gel matrix of crosslinked hyaluronic acid and carboxymethyl cellulose stably suspends calcium phosphate particles.

Formula I antiviral compounds improve solubility and bioavailability to overcome limited efficacy of existing influenza treatments.

Unsymmetrical pyrrolobenzodiazepine dimers overcome symmetrical structural limitations by forming sequence-selective DNA lesions for targeted treatment.

Local injection of necrotic tumor cell vaccine with checkpoint inhibitors reduces systemic toxicity while enhancing specific immune response.

Arginine-supplemented feed raises gill mucus viscosity and polysaccharide content, countering low viscosity from baths that limits therapeutic effectiveness.

Dietary supplement containing vitamin B6, folic acid, and trace elements to counteract hormonal contraceptive effects.

A melt-extruded pellet combines water-insoluble ammonium methacrylate copolymer and polyvinyl acetate to control active ingredient release.

A saw palmetto oil composition containing 3% w/w beta-sitosterol treats prostate disorders.

Modified siRNA maintains stability and biological activity while addressing adverse reactions and drug resistance in hepatitis B treatment.

Nucleophilic aromatic substitution enables synthesis of electron-deficient bis-THIQ analogs, overcoming electrophilic chemistry limitations.

Targeting NRF2 with NVP-BKM120 overcomes low survival rates in non-small cell lung cancer by enhancing radiation sensitivity.

Antisense oligomeric compounds block cryptic splice sites to restore wild-type GAA pre-mRNA splicing.

Liver-specific promoters drive transgene expression via rAAV vectors, maintaining stable blood phenylalanine levels without dietary restrictions.

Modified stem cells deliver cytotoxic payloads to overcome tumor stem cell resistance and eradicate cancer.

Novel deprenyl analogs inhibit nuclear GAPDH-Siah1 binding, reversing pathological effects in schizophrenia and cardiac hypertrophy models.

Anti-IL-6 antibodies extract resistant glioma stem cells by blocking survival signals, overcoming radiotherapy failure.

Targeting the transmembrane binding site separates pain relief from cannabinoid pathways, eliminating tolerance and dependence.

Anti-PD-1 antibodies block immune checkpoints to inhibit tumor growth and increase survival in lung cancer patients.

Segmented enteric coatings on lipid-suspended fumarate esters resolve coating uniformity contradictions and prevent sublimation losses.

A protein particle encapsulates a poorly water-soluble drug through controlled solvent dispersion and removal.

Pyrimidone carboxamide compounds selectively inhibit phosphodiesterase 2 to modulate cyclic nucleotide levels in neurons.

Modified terpene compounds inhibit TNF-alpha while limiting COX-2 activity, reducing adverse side effects from existing anti-inflammatory agents.

Chitin and chitosan diagnostic agents measure blood concentration to evaluate intestinal mucosa permeability directly.